Novartis AG
Novartis AG (NVS) is listed on NYSE and classified in Drug Manufacturers - General, part of the Healthcare sector. It is headquartered in Basel, Switzerland and has 75,267 employees. The company is worth $297.02B and trades at 23.6x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $56.67B in fiscal 2025, up 9.6% from the year before. Net income was $13.98B. The share price is 8.3% below its 52-week high of $170.46. It pays a dividend yielding 3.03%. 7 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Renaissance Technologies, at $123.5M. In that quarter, 4 of them opened or added to the position and 3 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▲ +89.0% over 5Y.
today you would have $2,194.60▲ +119.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $137.87 | $97.31 | $100.97 | $90.72 | |
| P/E | 17.9x | 19.3x | 16.6x | 14.2x | 28.6x |
| P/S | 4.4x | 4.6x | 3.7x | 4.4x | 4.4x |
| P/B | 4.4x | 5.7x | 4.4x | 4.4x | 3.2x |
| EPS | $7.15 | $5.87 | $7.10 | $3.17 | |
| Dividend yield | 3.57% | 2.90% | 3.84% | 3.44% | 3.70% |
| Payout | 59.79% | 55.86% | 63.71% | 48.86% | 105.90% |
| Profit margin | 23.88% | 24.67% | 23.09% | 31.83% | 16.00% |
| ROE | 28.71% | 30.31% | 27.11% | 31.82% | 11.72% |
Median of the years shown; P/E years above 200x are left out.
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings growing 25.0% a year plus a 3.0% dividend yield. Growth capped at 25%.
Median P/E of 24.3 among peers in the sector.
Median P/E of 17.9 across this company’s own years on record.
Cash flow growing 15.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
Dividend growing 5.5% a year against a 7.0% required return, from the stock’s beta.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
7 methods answered, across 4 families.
Room for errors in the reported numbers.
+32.4% from the average.
Models, not forecasts, and not investment advice. How each formula works →
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| AZNAstrazeneca PLC | $172.57 | 25.8x | 5.3x | 1.85% | 21.96% | $267.64B |
| TMOThermo Fisher Scientific Inc | $676.54 | 35.7x | 4.6x | 0.28% | 13.38% | $250.15B |
| MRKMerck & Co., Inc. | $147.24 | 116.9x | 8.7x | 2.31% | 6.96% | $363.27B |
| AMGNAmgen Inc | $447.28 | 27.2x | 20.7x | 2.25% | 91.47% | $241.81B |
| UNHUnitedhealth Group Inc | $424.98 | 26.8x | 3.7x | 2.18% | 15.77% | $381.46B |
| GILDGilead Sciences Inc | $157.19 | — | 16.5x | 2.09% | -20.68% | $194.91B |